Market closed · Next open: Monday 9:30 AM ET
Last update: Jul 24, 2026, 6:18 PM ET
Johnson & Johnson
$263.40 1.59% today
Market Closed

Why Johnson & Johnson (JNJ) stock moved

Updated Jul 25, 2026

Johnson & Johnson (JNJ) shares rose 1.6% to $263.40 as of July 25, 2026, a modest gain from the prior close of $259.27. BestStocks flagged the session as a material change for JNJ. The move is tied to a new SEC filing. Below, we break down what changed for JNJ, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

SEC Filing

Johnson & Johnson (JNJ) filed its quarterly 10-Q on July 23, 2026. Review the 10-Q filing for year-over-year revenue and earnings trends, segment performance, and any material changes in contingent liabilities or business risks.

This summary describes the catalyst and move as first detected on Jul 23, 2026, 4:49 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
FilingsSector-Wide MoveLow confidence
Rel. volume
0.8×
Below Avg
Vs peers
Top 1 of 7 peers
Outperforming
Market cap
$634.1B
New York Stock Exchange
Analyst target
$273
+3.5% vs price
Price chart
Jun 24 – Jul 24
FVFVVVVVV$241$254$268Jun 24Jul 1Jul 10Jul 17Jul 24
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Johnson & Johnson investors

For Johnson & Johnson investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.6% session move; Positive price momentum. Weighing against that: Johnson & Johnson (JNJ) moved -2.69% from $253.85 to $247.02 on 2026-07-15; JNJ fell 2.57% to $251.87 intraday despite posting first-quarter earnings that beat forecasts and raising full-year guidance. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in JNJ's fundamentals. Wall Street's consensus price target sits at $272.69, implying +3.5% upside from $263.40. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (50/100). With earnings roughly 80 days out, the next report is the most likely near-term test of the move.

JNJ price reaction

JNJ last traded at $263.40, up $4.13 (+1.59%) from the previous close of $259.27. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median +0.5% over the same stretch, leaving JNJ ahead of the group by 1.1 points. Over the past month the stock has ranged between $241.00 and $267.24, and it currently sits about 85% of the way up that band.

Bullish and bearish analyst opinions on Johnson & Johnson (JNJ)

Latest catalyststrengthens the bull case
The latest catalyst — a new SEC filing the market took well — it strengthens the bull case and confirms the prevailing bullish analyst lean.

The consensus analyst price target on Johnson & Johnson (JNJ) is $272.69, 3.5% above the recent $263.40. Over the past 90 days analysts logged 1 upgrade, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on JNJ line up.

The bullish case

  • Wall Street's consensus price target of $272.69 implies +3.5% upside from $263.40.
  • The Street's most bullish target is $305.00 (+15.8%).
  • 1 analyst upgrade in the past 90 days, most recently Leerink Partners to Outperform (2026-05-13).
  • Positive 1.6% session move.
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $220.00 (-16.5%).
  • Johnson & Johnson (JNJ) moved -2.69% from $253.85 to $247.02 on 2026-07-15.
  • JNJ fell 2.57% to $251.87 intraday despite posting first-quarter earnings that beat forecasts and raising full-year guidance.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Jul 25, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $273+3.5%
1 upgrades= 11 maintains
Guggenheim maintained Buy · 2026-07-17
SEC filings watch
10-Q2026-07-23
Quarterly financial results
medium
8-K2026-07-15
Material event — review for impact
high
8-K2026-04-28
Material event — review for impact
high
10-Q2026-04-22
Quarterly financial results
medium
Peer context
JNJ+1.6%
LLY+0.9%
UNH-0.7%
PFE-1.9%
ABBV+0.9%
MRK+0.5%

Previous notable changes for JNJ

Filings2026-07-15-2.7%
Johnson & Johnson (JNJ) filed a new 8-K on July 15, 2026. The audit found the filing announcement but did not disclose the specific event or item reported in the 8-K.
Risk2026-07-15-2.7%
Johnson & Johnson (JNJ) moved -2.69% from $253.85 to $247.02 on 2026-07-15. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be part of a sector-wide decline, with three major peers (ABBV -1.57%, UNH -2.46%, LLY -2.14%) moving in the same direction on the same day. Volume was modestly elevated at 1.5x the 5-day average.
Activity2026-07-07+3.1%via zacks.com
Johnson & Johnson gained 1.66% to $267.42 as investors positioned ahead of Q2 earnings due Wednesday, July 15 before market open (Benzinga). The advance reflects anticipation that the company will report higher Q2 earnings, with analysts revising forecasts; MedTech segment strength in cardiovascular, surgery, and vision is expected to test resilience against China VBP headwinds (Zacks). Volume data not yet reliable at 39 minutes into session.
Valuation2026-07-02+3.6%via zacks.com
JNJ rose 2.29% to $258.56 on intraday trading. The move aligns with a July 2 analyst-focused article highlighting Wall Street's bullish views on the stock, though the specific rating change or analyst upgrade details are not provided in available evidence.
Upcoming catalysts & outlook
Next earnings
2026-10-13 (est.)
in 80 days
10-Q Filing (est.)
2026-10-22
Medium impact
Thesis shift
Neutral / Mixed
bearish signal
Risk level
High
from change events

Frequently asked questions about JNJ

Why did Johnson & Johnson (JNJ) stock move?

JNJ rose 1.6% to $263.40. The move is associated with a new SEC filing and looks like a sector-wide move.

How much did JNJ stock rise?

JNJ gained 1.59% ($4.13) versus the prior close of $259.27, last trading at $263.40 on 0.8× average volume.

When is Johnson & Johnson's next earnings date?

JNJ's next earnings report is estimated for 2026-10-13 — about 80 days away.

What is the analyst price target for JNJ?

The consensus analyst price target for JNJ is $272.69, about 3.5% above the current $263.40. Over the past 90 days, analysts recorded 1 upgrade, 11 maintains, and 0 downgrades.

Is the JNJ move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median +0.5% against JNJ's +1.6%. JNJ ranks top 1 of 7 peers.

How BestStocks tracks JNJ

This page is generated automatically by BestStocks' change-detection system after a new SEC filing was detected and verified against independent data sources. It draws on 10 tracked change events for JNJ, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 25, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.